Awaiting development: Guidance and quality standards

Showing 171 to 180 of 307

Guidance and quality standards awaiting development
Title	Type
Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941	Technology appraisal guidance
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]	Highly specialised technology
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]	Technology appraisal guidance
Oveporexton for treating type 1 narcolepsy [ID6622]	Technology appraisal guidance
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]	Technology appraisal guidance